|
Invited Speakers:
|
|
- Uwe Schoenbeck, Chief Scientific Officer, ERDI Worldwide Research and Development, Pfizer, Inc.
- Fred Hassan, Partner and Managing Director, Warburg Pincus, Board Member, Valeant Pharmaceuticals International, Inc., Board Member, Time Warner, Former Chairman of the Board and CEO, Schering-Plough Corporation
- Bernard Davitian, Vice President and Managing Director, Sanofi-Genzyme BioVentures
- Darryle Schoepp, PhD, SVP & Franchise Head, Neuroscience, Merck & Co, Inc.
- Timothy Herpin, Vice President Strategic Planning and Business Development, Oncology, AstraZeneca
- Anne Altmeyer, PhD, MBA, MPH, Vice President, Business Development & Licensing, Oncology, Novartis Pharmaceuticals Corporation
- Tariq Kassum, MD, Vice President, Corporate Development Oncology, Millennium Pharmaceuticals, The TAKEDA Oncology Company
- Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing, Business Development and Alliance Management, EMD SERONO, Inc.
- Ulrich Thienel, Vice President, Therapeutic Area Leader Immunology and Respiratory, Takeda Pharmaceuticals
- Carolyne Zimmermann, Head, Search Evaluation and Negotiations, Critical Care Franchise Executive Director, Global Business Development and Licensing, Novartis Pharmaceuticals
- Samantha O'Connor, Senior Director, Business Development, Pfizer, Inc.
- Jeffrey Warmke, PhD, Senior Vice President, External Scientific Affairs, Daiichi Sankyo Group
- Jacques Dumas, PhD, Vice President and Head of Strategy Infection Innovative Medicines, AstraZeneca
- Jeffrey B. Ulmer, PhD, Global Head of External Research, Novartis Vaccines & Diagnostics
- Kevin Anderson, Global Head Virology Partnering, Roche
- Sridaran Natesan, PhD, Vice President for External Innovation, Sanofi
- John Delyani, Head Therapeutics and Technologies, Strategic Alliances, Novartis
- Kumar Srinivasan, Vice President, Scientific Partnering & Alliances, AstraZeneca
- Sam Rasty, PhD, Vice President, New Products, Rare Disease Business Unit, Shire
- Joseph S. McCracken, DVM, Former Global Head for Business Development and Licensing, Roche
- Michelle Dipp, MD, PhD, CEO, OvaScience, Inc.
|
|